Compare Cassava Sciences Inc (FLNA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while State Street SPDR S&P Homebuilders ETF trades at $94.78 (market cap $1.49B). The key difference: State Street SPDR S&P Homebuilders ETF is far larger — about 37.8× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 2,445,587). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| FLNA | XHB | |
|---|---|---|
Market Cap | $39.40M | $1.49B |
Volume | 759,018 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $121.36 |
52-Week Low | $0.68 | $94.86 |
Typical Hold Time | 37 Days | 33 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.65, down 0.25% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but potential tailwinds from new housing affordability legislation and institutional interest.
The outlook for XHB is mixed, balancing sector-specific risks like rising rates against legislative support and valuation opportunities. Investment appeal hinges on a housing market recovery, with risks including economic sensitivity and inventory constraints. Sentiment is cautious but notes historical buying signals at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
